Physostigmine and cognition in schizotypal personality disorder.
There is evidence that reduced cholinergic activity may play a role in the pathophysiology of cognitive impairment in the schizophrenia spectrum. We tested the effects of physostigmine, an anticholinesterase inhibitor, on visuospatial working memory as evaluated by the Dot test, and on verbal learning and recall as measured by a serial learning task in patients with schizotypal personality disorder. Physostigmine tended to improve the Dot test, but not serial verbal learning performance in these patients.
Department of Psychiatry, Mount Sinai Medical Center, Bronx Veterans' Administration Medical Center, New York, NY, USA.
R M
RM
Kirrane
V
V
Mitropoulou
M
M
Nunn
J
J
Silverman
L J
LJ
Siever
D000328:Adult; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008570:Memory, Short-Term / Q000187:drug effects*; D010830:Physostigmine / Q000627:therapeutic use*; D012569:Schizotypal Personality Disorder / Q000188:drug therapy*; D013028:Space Perception / Q000187:drug effects; D014796:Visual Perception / Q000187:drug effects
D002800:Cholinesterase Inhibitors; D010830:Physostigmine